Skip to main content
Clinical Trials/NCT04197388
NCT04197388
Unknown
Not Applicable

Inspiratory Muscle Training in Pulmonary Arterial Hypertension

Golden Jubilee National Hospital1 site in 1 country20 target enrollmentJune 26, 2019

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Pulmonary Hypertension
Sponsor
Golden Jubilee National Hospital
Enrollment
20
Locations
1
Primary Endpoint
Six minute walking distance
Last Updated
6 years ago

Overview

Brief Summary

Pulmonary arterial hypertension is a rare condition characterised by high blood pressure in the lungs and results in breathlessness and reduced exercise capacity for patients. Previous research has shown weakness in respiratory muscles in these patients that may contribute towards their symptoms. Despite advances in medical therapy, the condition still results in a significant symptom burden.

Inspiratory muscle training is a non-invasive intervention involving a device that provides resistance to the muscles of inspiration and increases their strength.

This study will investigate the benefit of inspiratory muscle training in patients with pulmonary arterial hypertension who are stable on medical therapy for three months. This will be performed as an outpatient and they will then be reviewed following this with assessment of exercise capacity, breathing capacity (spirometry), quality of life, and assessment of neural respiratory drive (the signals from the brain to the muscles controlling breathing).

The study will be based at the Golden Jubilee National Hospital and patients will be recruited from outpatients who are already under the care of the Scottish Pulmonary Vascular Unit.

Registry
clinicaltrials.gov
Start Date
June 26, 2019
End Date
April 1, 2021
Last Updated
6 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • diagnosed by pulmonary hypertension specialist with precapillary pulmonary hypertension
  • able to give consent
  • stable on medical therapy for at least 3 months

Exclusion Criteria

  • significant contribution to pulmonary hypertension from lung disease

Outcomes

Primary Outcomes

Six minute walking distance

Time Frame: 3 months

Secondary Outcomes

  • VE/VCO2 slope(3 months)
  • Quality of life: emPHasis 10 score(3 months)
  • Peak VO2(3 months)

Study Sites (1)

Loading locations...

Similar Trials